BioCryst Pharmaceuticals

Yahoo Finance • 24 days ago

BioCryst Pharmaceuticals Q1 Earnings Call Highlights

BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described as a strong start to 2026, driven by continued growth of hereditary angioedema (HAE) therapy ORLADEYO and progress across its developm... Full story

Yahoo Finance • last month

Organon (OGN) Takeover Bid Climbs to $13B, Shares Soar 30.9%

Organon & Co. (NYSE:OGN) is one of the 10 High-Flying Stocks With Double-Digit Returns. Organon bounced back by 30.93 percent on Friday to close at $11.26 apiece, as investors snapped up shares following news that Sun Pharmaceuticals is u... Full story

Yahoo Finance • last month

BioCryst to Report First Quarter 2026 Financial Results on May 6

RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026. BioCryst ma... Full story

Yahoo Finance • 2 months ago

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst Pharmaceuticals, Inc. — Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceu... Full story

Yahoo Finance • 2 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?

Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.'s share was trading at $9... Full story

Yahoo Finance • 3 months ago

BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 2, Wedbush analyst Laura Chico increased the firm’s price target on BioCryst Pharmaceuticals Inc. (NASDAQ:B... Full story

Yahoo Finance • 3 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newl... Full story

Yahoo Finance • 3 months ago

BioCryst (BCRX) Soars 10.8% on Swing to Profits

We recently published 10 Stocks Ending February With a Bang. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) was one of the best performers on Friday. BioCryst surged by 10.76 percent on Friday to close at $8.75 apiece, as investor sentiment... Full story

Yahoo Finance • 3 months ago

BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances

Earnings Call Insights: BioCryst Pharmaceuticals (BCRX) Q4 2025 MANAGEMENT VIEW * Charles Gayer, CEO, emphasized, "We closed 2025 with strong momentum, delivering full-year ORLADEYO revenue of $601.8 million. That was up 38% for the ye... Full story

Yahoo Finance • 3 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Viatris (VTRS [https://seekingalpha.com/symbol/VTRS]) * Baidu (BIDU [https://seekingalpha.com/symbol/BIDU]) * Vistance Networks (VISN [https://seekingalpha.com/symbol/VI... Full story

Yahoo Finance • 3 months ago

BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed?

Evercore ISI recently reinstated coverage of BioCryst Pharmaceuticals, highlighting the company’s position after its acquisition of Astria Therapeutics and its hereditary angioedema portfolio, including ORLADEYO and navenibart. BioCryst is... Full story

Yahoo Finance • 5 months ago

H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best small cap stocks to buy with huge upside potential. H.C. Wainwright lifted the price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $32 from $30 on December 15, and r... Full story

Yahoo Finance • 6 months ago

Catalyst Watch: Spotlight on the Fed, Costco earnings, and Nasdaq 100 additions

[Amazing golden hour in modern New York. Sunset time footage from drone. Setting sun dazzles the scenery.] Vadym Terelyuk/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable ev... Full story

Yahoo Finance • 6 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements... Full story

Yahoo Finance • 6 months ago

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 7 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * ON Semiconductor Corporation (ON [https://seekingalpha.com/symbol/ON]) * Oxford Lane Capital Corp. (OXLC [https://seekingalpha.com/symbol/OXLC]) * fuboTV (FUBO [https://se... Full story

Yahoo Finance • 7 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

BALA CYNWYD, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 7 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)

BALA CYNWYD, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 7 months ago

Key deals this week: Paramount Skydance, PotlatchDeltic, Brighthouse Financial, Papa John's and more

Here's a list of key deals reported across sectors this week: * Paramount Skydance (NASDAQ:PSKY [https://seekingalpha.com/symbol/PSKY]) is preparing a second bid [https://seekingalpha.com/news/4503595-paramount-skydance-preparing-second... Full story

Yahoo Finance • 7 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)

BALA CYNWYD, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story